Piperazine, piperidine and tetrahydropyridine derivative of
indol-3-alkyl as 5-HT.sub.1D-.alpha. agonists
    2.
    发明授权
    Piperazine, piperidine and tetrahydropyridine derivative of indol-3-alkyl as 5-HT.sub.1D-.alpha. agonists 失效
    吲哚-3-烷基的哌嗪,哌啶和四氢吡啶衍生物作为5-HT1D-α激动剂

    公开(公告)号:US5807857A

    公开(公告)日:1998-09-15

    申请号:US737769

    申请日:1996-11-15

    摘要: Compounds of formula (I), or a salt or prodrug thereof, wherein Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms, optionally substituted in any position by a hydroxy group; T represents nitrogen or CH; U represents nitrogen or C--R.sup.2 ; V represents oxygen, sulphur or N--R.sup.3 ; --F--G-- represents --CH2--N--, --CH2--CH-- or --CH.dbd.C--; R.sup.1 represents C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, aryl(C.sub.1-6)alkyl or heteroaryl(C.sub.1-6)alkyl, any of which groups may be optionally substituted; and R.sup.2 and R.sup.3 independently represent hydrogen or C.sub.1-6 alkyl are selective agonists of 5-HT1D receptors, being potent agonists of the human 5-HT1Dalpha receptor subtype, while possessing at least a 10-fold selective affinity for the 5-HT1Dalpha receptor subtype, relative to the 5-HT1Dbeta subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.

    摘要翻译: PCT No.PCT / GB95 / 01129 Sec。 371日期1996年11月15日 102(e)日期1996年11月15日PCT提交1995年5月18日PCT公布。 公开号WO95 / 32196 (I)式(I)化合物或其盐或前药,其中Z表示选自呋喃,噻吩,吡咯,恶唑,噻唑,异恶唑的任选取代的五元杂芳环 ,异噻唑,咪唑,吡唑,恶二唑,噻二唑,三唑和四唑; E表示化学键或含有1至4个碳原子的直链或支链亚烷基链; Q表示任选被羟基取代的含有1至6个碳原子的直链或支链亚烷基链; T表示氮或CH; U表示氮或C-R2; V表示氧,硫或N-R3; -F-G-表示-CH 2 -N,-CH 2 -CH-或-CH = C-; R 1表示C 3-6烯基,C 3-6炔基,芳基(C 1-6)烷基或杂芳基(C 1-6)烷基,其中任何基团可以任选被取代; 并且R 2和R 3独立地表示氢或C 1-6烷基是5-HT1D受体的选择性激动剂,它是人5-HT1Dalpha受体亚型的有效激动剂,同时对5-HT1Dalpha受体亚型具有至少10倍的选择性亲和力, 相对于5-HT1Dbeta亚型; 因此,它们可用于治疗和/或预防临床症状,特别是偏头痛和相关疾病,其中指出5-HT1D受体的亚型选择性激动剂,同时引起较少的副作用,特别是不利的心血管事件,比 与非亚型选择性5-HT1D受体激动剂相关的那些。

    Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor
agonists
    3.
    发明授权
    Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor agonists 失效
    氮杂环丁烷,吡咯烷和哌啶衍生物作为5-HT受体激动剂

    公开(公告)号:US6140347A

    公开(公告)日:2000-10-31

    申请号:US171208

    申请日:1998-10-14

    摘要: A class of compounds of formula (I) wherein Z, E, Q, T, U, V, W, M, R.sup.1, R.sup.7 and R.sup.8 are as defined herein; are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists. ##STR1##

    摘要翻译: PCT No.PCT / GB97 / 01137 Sec。 371日期:1998年10月14日 102(e)日期1998年10月14日PCT 1997年4月24日PCT公布。 出版物WO97 / 42189 日期:1997年11月13日一类其中Z,E,Q,T,U,V,W,M,R 1,R 7和R 8如本文所定义的式(I)化合物; 是5-HT1样受体的选择性激动剂,其是人类5-HT1Dα受体亚型的有效激动剂,同时相对于5-HT1Dβ亚型对5-HT1Dα受体亚型具有至少10倍的选择性亲和力; 因此,它们可用于治疗和/或预防临床状况,特别是偏头痛和相关疾病,其中指出5-HT1D受体的亚型选择性激动剂,同时引起较少的副作用,特别是不利的心血管事件,比 与非亚型选择性5-HT1D受体激动剂相关的那些。

    Benzodiazepine derivatives
    8.
    发明授权
    Benzodiazepine derivatives 失效
    苯并二氮杂衍生物

    公开(公告)号:US5681833A

    公开(公告)日:1997-10-28

    申请号:US302936

    申请日:1994-09-20

    摘要: Compounds of Formula (I), and salts and prodrugs thereof, wherein said formula, R.sup.1 represents certain optionally substituted alkyl or C.sub.3-7 cycloalkyl; R.sup.2 represents (II) or (III), where m is 0, 1, 2 or 3; R.sup.9 is H or C.sub.1-6 alkyl; R.sup.10 is imidazolyl, triazolyl or tetrazolyl, and R.sup.11 is H, C.sub.1-6 alkyl or halo; R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ; R.sup.4 is C.sub.1-7 alkyl, C.sub.3-10 cycloalkyl, C.sub.3-10 cycloalkylC.sub.1-4 alkyl, C.sub.6-10 bicycloalkyl, optionally substituted aryl, or NR.sub.12 R.sub.13 ; R.sup.5 is H or C.sub.1-4 alkyl; n is 0, 1, 2 or 3; which are CCK and/or gastrin antagonists useful in therapy.

    摘要翻译: PCT No.PCT / GB93 / 00599 Sec。 371日期1994年9月20日 102(e)1994年9月20日PCT 1993年3月23日PCT公布。 出版物WO93 / 19052 (III)式(I)化合物及其盐和前药,其中所述式R1表示某些任选取代的烷基或C 3 -C 10烷基, 7环烷基; R2表示(II)或(III),其中m为0,1,2或3; R9是H或C1-6烷基; R10是咪唑基,三唑基或四唑基,R11是H,C1-6烷基或卤素; R3是C1-6烷基,卤素或NR6R7; R 4是C 1-7烷基,C 3-10环烷基,C 3-10环烷基C 1-4烷基,C 6-10二环烷基,任选取代的芳基或NR 12 R 13; R5是H或C1-4烷基; n为0,1,2或3; 其是可用于治疗的CCK和/或胃泌素拮抗剂。